

CLAIM LISTING

1-69. (Canceled)

70. (Previously presented) A host cell comprising nucleic acid sequences encoding the light chain and the heavy chain of an immunologically active chimeric anti-CD20 antibody, wherein the sequence encoding the light chain comprises a nucleotide sequence encoding amino acid residues 23 to 128 of SEQ ID NO: 4, and the sequence encoding the heavy chain comprises a nucleotide sequence encoding amino acid residues 20 to 140 of SEQ ID NO: 6.

71. (Previously presented) The host cell of claim 70 wherein the sequence encoding the light chain further comprises a nucleotide sequence encoding a human kappa light chain constant region, and the sequence encoding the heavy chain further comprises a nucleotide sequence encoding a human gamma 1 heavy chain constant region.

72. (Previously presented) The host cell of claim 71 wherein the cell is capable of producing an immunologically active chimeric anti-CD20 antibody.

73. (Previously presented) The host cell of claim 72 which is a mammalian cell.

74. (Previously presented) The host cell of claim 73 which is a Chinese Hamster Ovary (CHO) cell.

75. (Previously presented) The host cell of claim 73 which is an SP2/0 cell.

76. (Previously presented) A method of making a purified antibody comprising expressing the light and heavy chains encoded by the nucleic acid sequences in the host cell of claim 72 and purifying the antibody produced by the host cell.

77. (Previously presented) The method of claim 76 further comprising combining the purified antibody with a pharmaceutically acceptable buffer.

78. (Previously presented) The method of claim 76 further comprising combining the purified antibody with a pharmaceutical carrier.

79-97. (Canceled)